Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Our knowledge about risk factors of atherosclerosis and their associations has considerably changed and improved. The importance of type 2 diabetes and hypertension was detected earlier, hyperlipidemia and dyslipidemia (disturbance of lipoprotein composition) have been recently implemented. We have learnt that the android obesity form and especially visceral fat serve as central trigger-factor of the resulting "metabolic syndrome" and other related disturbances like acute phase proteins, inflammation markers and procoagulatory state. Altogether atherothrombotic events are increased and result in clinically relevant macrovascular disease (myocardial infarction, cerebrovascular und peripheral arterial disease), blood glucose itself causing additionally microvascular disease. The newest comprehensive guidelines of European Associations try to use most of the known factors for treatment guidelines but will fail due to the fact that they cannot be easily used in clinical practice. In additon, visceral fat, that central factor, and body fat mass have not been integrated. We suggest that the risk should be evaluated in the context of body mass index (BMI) and especially of waist circumference which could be THE central intervention factor in the treatment of our patients.
 ...
PMID:[Metabolic syndrome--a high cardiovascular risk?]. 1551 78

THE PREGNANT PATIENT: Age; maternal disease; prophylactic antibiotics; gastroesophageal reflux; obesity; starvation; genotyping; coagulopathy; infection; substance abuse; altered drug responses in pregnancy; physiological changes of pregnancy. THE FETUS: Fetal monitoring; intrauterine surgery. THE NEWBORN: Breastfeeding; maternal infection, fever, and neonatal sepsis evaluation. OBSTETRIC COMPLICATIONS: Embolic phenomena; hemorrhage; preeclampsia; preterm delivery. OBSTETRIC MANAGEMENT: External cephalic version and cervical cerclage; elective cesarean delivery; fetal malpresentation; vaginal birth after cesarean delivery; termination of pregnancy. OBSTETRIC ANESTHESIA: Analgesia for labor and delivery; anesthesia for cesarean delivery; anesthesia for short obstetric operations; complications of anesthesia. MISCELLANEOUS: Consent; ethics; history; labor support; websites/books/leaflets/journal announcements.
 ...
PMID:What's new and novel in obstetric anesthesia? Contributions from the 2003 scientific literature. 1579 48

WHEN A PATIENT IS OBESE, simple dieting and exercise are rarely able to reverse significant comorbidities. Currently, surgery is the most effective treatment for obesity with respect to the amount and duration of weight loss. BARIATRIC SURGERY REQUIRES a team approach in a clinical setting capable of supporting all aspects of management and assessment. THE PATIENT IS THE CENTER of the team's focus, and all facets of the perioperative process are interconnected. The words coordinate, educate, accommodate, facilitate, and communicate describe the multidisciplinary process that is necessary to provide quality, safe patient care with positive outcomes.
 ...
PMID:A perioperative team approach to treating patients undergoing laparoscopic bariatric surgery. 1860 33

APPROXIMATELY TWO-THIRDS of the US population is overweight or obese. The effects of the comorbidities that accompany obesity often are severe and can be life threatening over time. Currently, the most effective and sustainable method of substantial weight loss is bariatric surgery. Bariatric surgery also has been successful in reversing comorbidities. THE BENEFITS, RISKS, AND COMPLICATIONS of common weight-loss surgical procedures (eg, Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding, vertical-banded gastroplasty, biliopancreatic diversion and duodenal switch) are discussed. THE HEALTH CARE FIELD OF BARIATRICS is growing rapidly. More information is needed to support and guide changes in current standards of practice to better meet the needs of this patient population.
 ...
PMID:Perioperative nursing care of the bariatric surgical patient. 1867 49

As the prevalence of obesity and diabetes are continually increasing, the use of "false sugars" otherwise known as sweeteners, and their associated health issues are being more and more discussed. A higher sugared power, less calories as well as a moderated or non-existent effect on blood sugar would lead to believe that sweeteners are helpful. However, we CANNOT say that they are THE solution as they can contain calories, may have some undesired effects, and moreover they ease the conscience without actually allowing a weight loss with their sole use. They are to be used with judgment, wittingly and especially when comparing sweetened products. The sweetener myth is often far from reality. It is therefore important to give our patients the means to analyze their dietary intake with regard to their sweeteners ingestion.
 ...
PMID:[Sweeteners: between myth and reality]. 1946 12

THIS PAPER PRESENTS AN ANALYSIS OF THE RECENTLY PUBLISHED JUSTIFICATION FOR THE USE OF STATINS IN PREVENTION (JUPITER: an intervention trial evaluating rosuvastatin) trial, which tested the statin rosuvastatin in apparently healthy individuals with no prior cardiovascular (CVD) disease and with normal plasma low density lipoprotein (LDL) cholesterol concentrations but with raised plasma high sensitivity C-reactive protein (hsCRP) levels. The rate of the combined primary CVD endpoint was significantly reduced in the treatment arm after a median of under 2 years. The JUPITER trial is distinct from previous studies examining statin use in primary prevention groups because the target group for drug therapy was apparently healthy men and women at low or intermediate risk for developing CVD. On the basis of JUPITER's findings, there are key questions that should be assessed on the therapeutic intervention of CVD regarding: the primary prevention groups that should be targeted for statin therapy, the utility of targets in addition to plasma LDL cholesterol levels, and the need to consider the metabolic state of individuals targeted for therapy (including the presence of obesity and inflammation). The conclusion from the current analysis is that the JUPITER results warrant further LDL cholesterol lowering than is currently targeted in primary prevention groups that have a pre-existing condition or lifestyle that elevates CVD risk but still do not have a high global CVD risk (as assessed with current algorithms). This group is not captured in current widely used CVD risk calculations, however, with the identification of useful biomarkers, such as hsCRP, this group can be better identified and targeted for intervention.
 ...
PMID:Key questions resulting from the JUPITER trial assessing cardiovascular disease intervention with rosuvastatin. 2116 May 75

THE DEVELOPMENT OF HYPERTENSION CAN BE PREDICTED BY SUCH FACTORS AS: age, salt, alcohol and fiber intake, obesity, physical activity, psychosocial factors, and family history of hypertension or premature cardiovascular disease. Blood pressure response to stressful stimuli is also an important predictor. Research should focus on better assessment and management of predictors including psychosocial factors which increase blood pressure, and personality characteristics that increase sensitivity to stressful stimuli. Since inheritance of blood pressure may be considerable, detecting a hypertensive patient should stimulate the family physician to measure blood pressure of other family members. Future management of hypertension may involve increased public health activity to improve detection, education and management in the community while more efficient office management integrates the patient into the decision making process.
 ...
PMID:Predicting and preventing hypertension and associated cardiovascular disease. 2127 10

FOR MANY OF US, OBESITY IS THE OUTCOME OF AN ENERGY IMBALANCE: more energy input than expenditure. However, our waistlines are growing in spite of the huge amount of diets and fat-free/low-calorie products available to cope with this issue. Even when we are able to reduce our waistlines, maintaining the new size is very difficult: in the year after the end of a nutritional and/or behavioral treatment obese persons typically regain from 30% to 50% of their initial losses. A possible strategy for improving the treatment of obesity is the use of advanced information technologies. In the past, different technologies (internet, virtual reality, mobile phones) have shown promising effects in producing a healthy lifestyle in obese patients. Here we suggest that a new technological paradigm - Interreality - that integrates assessment and treatment within a hybrid experiential environment - including both virtual and real worlds - has the potential to improve the clinical outcome of obesity treatments. The potential advantages offered by this approach are: (a) an extended sense of presence: Interreality uses advanced simulations (virtual experiences) to transform health guidelines and provisions in experiences; (b) an extended sense of community: Interreality uses virtual communities to provide users with targeted - but also anonymous, if required - social support in both real and virtual worlds; (c) real-time feedback between physical and virtual worlds: Interreality uses bio and activity sensors and devices (smartphones) both to track in real time the behavior/health status of the user, and to provide targeted suggestions and guidelines. This paper describes in detail the different technologies involved in the Interreality vision. In order to illustrate the concept of Interreality in practice, a clinical scenario is also presented and discussed: Daniela, a 35-year-old fast-food worker with obesity problems.
 ...
PMID:Interreality: the experiential use of technology in the treatment of obesity. 2155 36

New revelations that have revitalized obesity-related research using a peripheral approach prompted us to organize a workshop titled "The intestinal wall - THE regulatory interface in energy homeostasis," which was held June 20-25, 2010, in Ascona, Switzerland, at the Centro Stefano Franscini of the Swiss Federal Institute of Technology (ETH). Throughout an exciting week of seminars and discussions, the workshop brought together around 70 expert researchers and clinicians from around the world who attempted to evaluate and integrate many important aspects of the role of the digestive tract in the regulation of energy homeostasis at the molecular, cellular, and systemic levels, as well as the implications for the prevention or treatment of obesity.
 ...
PMID:Introduction to "The intestinal wall - THE regulatory interface in energy homeostasis". 2171 11

THE BARKER HYPOTHESIS: Is an excellent explanation of the process where human and animal foetuses exposed to malnutrition, either by maternal malnutrition or placental insufficiency, are metabolically programmed, with selective stunting of cell differentiation and organ growth. With the postnatal excess of nutrition observed in developed countries, this irreversible programming causes metabolic syndrome, including obesity, type 2 diabetes, and hypertension. Metabolic programming involves epigenetic changes including imprinting which might be transmitted through more than one generation rather than being completely re-set or erased during reproduction. The Barker hypothesis was supported by epidemiological data that recognised no excess fetal or postnatal mortality when pregnant women were starved during the Dutch famine in World War II. This argued against the "thrifty genotype" theory introduced in 1962, which proposed that starvation selected against members of the population with less "thrifty" genes, but the survivors who had "thrifty" genes developed metabolic syndrome if they were subsequently over-nourished. EMBRYONIC/FETAL SELECTION: Embryos or early foetuses could be selected very early in pregnancy on the basis of their genotype, by maternal malnutrition, hypertension, obesity or other causes of placental insufficiency. The genotype that allows embryos, or cells within them, to survive a less hospitable environment in the decidua after implantation might contribute to the later development of metabolic syndrome. This article hypothesises that an adverse intrauterine environment, caused by maternal malnutrition or placental insufficiency, kills a proportion of embryos and selects a surviving population of early embryos whose growth in utero is retarded by their genotype, their environment or a combination of both. The metabolic syndrome follows if the offspring is over-nourished later in life. The embryonic selection hypothesis presented here could be tested by using single nucleotide polymorphism (SNP) microarrays to study adults who had a history of intrauterine growth retardation (IUGR) and subsequent metabolic syndrome. Their SNP array could be compared with their parents and unaffected unrelated or related controls. If there were no selection based on a "thrifty genotype", all parental sequences would be expected to appear in their surviving children, whether or not they had IUGR or developed metabolic syndrome. SNP sequences present in parents or controls but missing from adult offspring with metabolic syndrome who had IUGR, could be associated with or linked to genes that influence susceptibility to metabolic syndrome. This hypothesis proposes that missing genotypes would be lost if the embryos that inherited them died very early in pregnancy.
 ...
PMID:Genetic selection of embryos that later develop the metabolic syndrome. 2234 93


<< Previous 1 2 3 4 5 Next >>